Skip to content

Glaukos

US · GKOS #1500 by market cap Listed 2015
172.18 +10.59 +6.55%
Live - 5344 symbols - heartbeat 222s ago · 2026-10-08 04:00
Pre-market 172.18 0.00%
After-hours 172.18 0.00%
Overnight 170.79 -0.81%
Market cap
10.16B
P/B
14.88
EPS
-3.28
Reader sentiment Are you bullish or bearish on GKOS?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 13.99 Expensive vs history 95th percentile
5-year average 7.76 · #116 of 125 in Medical Devices
P/E ratio -49.50 Cheap vs history 31st percentile
5-year average -43.01 · forward -844.28
P/S ratio 15.58 Expensive vs history 78th percentile
5-year average 12.80 · forward 12.59 · #120 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Glaukos (GKOS) 10.16B -52.65 14.88 0.00%
Abbott Laboratories (ABT) 170.84B 31.95 3.34 2.47%
Medtronic (MDT) 109.38B 21.06 2.18 3.33%
Stryker Corp (SYK) 105.64B 28.54 4.40 1.26%
Boston Scientific (BSX) 60.26B 16.83 2.42 0.00%
Edwards Lifesciences (EW) 49.44B 49.87 4.66 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value137.18 Economic moatNone UncertaintyHigh

Trading 20.3% above Morningstar's fair value estimate.

Fair value

Glaukos Corp is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 20% premium over our quantitative fair value estimate of $137.18 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's lack of profitability decreases our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 6.5% falls in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are expensive.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 7.1%, a core component of valuation, lies in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 04:00:14 · For reference only, not investment advice and not tailored to your situation.